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Abstract 
Background: The biological mechanisms of headache chronification are poorly 
understood. We aimed to identify changes in DNA methylation associated with the 
transformation from episodic to chronic headache. 
 
Methods: Participants were recruited from the population-based Norwegian HUNT-
Study. Thirty-six female headache patients who transformed from episodic to chronic 
headache between baseline and follow-up 11 years later were matched against 35 
controls with episodic headache. DNA methylation was quantified at 485,000 CpG 
sites, and changes in methylation level at these sites were compared between cases 
and controls by linear regression analysis. Data were analyzed in two stages (Stages 1 
and 2) and in a combined meta-analysis. 
 
Results: None of the top 20 CpG sites identified in Stage 1 replicated in Stage 2 after 
multiple testing correction. In the combined meta-analysis the strongest associated 
CpG sites were related to SH2D5 and NPTX2, two brain-expressed genes involved in 
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the regulation of synaptic plasticity. Functional enrichment analysis pointed to 
processes including calcium ion binding and estrogen receptor pathways. 
 
Conclusion: In this first genome-wide study of DNA methylation in headache 
chronification several potentially implicated loci and processes were identified. The 
study exemplifies the use of prospectively collected population cohorts to search for 
epigenetic mechanisms of disease. 
 
Key words: chronic headache; epigenetics; cohort studies 
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Introduction 
In a number of patients who suffer from episodic headache attacks, their headache 
transforms into a chronic form (1, 2). Chronic headache, defined as headache 
occurring on at least 15 days per month, affects 3-5% of the general population and 
40% of patients in headache clinics, and is associated with severe disability and 
impaired quality of life (1, 3). Approximately half of these patients have chronic 
migraine (1). Established risk factors for headache chronification include the overuse 
of acute headache medications and a high baseline attack frequency (4). The 
biological mechanisms involved in the transition from episodic to chronic headache 
are however unknown. 
 
In recent years it has become evident that epigenetic processes play an important role 
in a range of multifactorial diseases (5). Epigenetics entail changes in gene expression 
that are not due to variation in the DNA sequence. A main epigenetic mechanism is 
DNA methylation, the covalent addition of a methyl group to the 5th carbon of 
cytosine residues, which is typically associated with gene silencing (5, 6). Epigenetic 
modifications can be stably inherited through cell divisions but can also be dynamic. 
They enable cell and developmental stage-specific regulation of gene expression, and 
play an important role in programming lasting responses to environmental cues (6, 7). 
Due to the ability of DNA methylation changes to shift a biological system from one 
stable state to another, their implication in headache chronification is of particular 
interest. It has been hypothesized that frequent headache attacks may lower the 
threshold for subsequent headache attacks through epigenetic mechanisms resulting in 
a feed-forward loop (6). Similarly, psychological stress and female sex hormones, 
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which have been implicated in migraine genesis, are known to exert their 
physiological effects partly through epigenetic mechanisms (6, 8).  
 
In this study, subjects were recruited from the Norwegian population-based Nord-
Trøndelag Health (HUNT) Study, where they gave blood samples and were assessed 
for headache at two time points 11 years apart. In order to identify changes in DNA 
methylation associated with headache chronification we compared cases, who 
transformed from episodic to chronic headache during the follow-up period, with 
controls who did not develop chronic headache. For all selected subjects, genome-
wide DNA methylation levels were characterized at baseline and follow-up.  
 
Materials and Methods 
Participants 
In the HUNT2 (1995–1997) and HUNT3 (2006–2008) studies, the entire population 
of the Norwegian county of Nord-Trøndelag, 20 years of age or older, was invited to 
complete extensive questionnaires concerning health-related issues, participate in a 
clinical examination and donate blood samples. Among 92,566 individuals in HUNT2 
and 94,194 in HUNT3 invited to participate, 51,383 (56%) and 39,701 (42%), 
respectively, answered the headache questionnaire (9, 10).  
 
The headache classification used in this study has been described in detail elsewhere 
(9-11). Briefly, in each survey those who answered 'yes' to the screening question 
‘Have you suffered from headache during the last year?’ were defined as headache 
sufferers and asked to fill in the other headache questions. Participants indicated the 
number of days with headache per month, with the options < 7, 7-14 or > 14 
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days/month in HUNT2 and the options < 1, 1-6, 7-14 or > 14 days/month in HUNT3. 
Chronic daily headache (CDH) was defined as headache occurring on ≥ 15 
days/month. In HUNT2, acute medication overuse was defined as ‘analgesic use daily 
or almost daily for ≥ 1 month during the last 12 months’, and in HUNT3 as ‘over-the-
counter-medication use for headache ≥ 4 days/week during the last month’. 
Medication-overuse headache was defined as the combination of CDH and acute 
medication overuse (9, 11, 12). This headache classification has been validated by 
interview diagnoses (9, 10). In HUNT2, the sensitivity and specificity were, 
respectively 85% and 83% for headache suffering (Cohen's kappa κ = 0.57), and 91% 
and 56% for headache frequency < 7 days per month (κ = 0.50). In HUNT3, the 
sensitivity and specificity were, respectively 88% and 86% for headache suffering (κ 
= 0.70), 69% and 99% for CDH (κ = 0.75) and 75% and 100% for medication-
overuse headache (κ = 0.75). 
 
Cases for the current study were selected among participating women who at the time 
of HUNT2 (baseline) were ≤ 35 years of age and reported headache on < 7 
days/month, and at the time of HUNT3 (follow-up) reported ≥ 15 headache 
days/month (CDH). To avoid sample heterogeneity resulting from different DNA 
methylation patterns in men and women, only women were included. Likewise, to 
avoid DNA methylation changes resulting from the onset of menopause during 
follow-up only women ≤ 35 years of age at baseline were included. In total 43 
subjects fulfilled these criteria. After excluding samples with missing DNA from 
either baseline or follow-up, 40 cases were included in the study. We selected an 
equal number of controls, who were matched with cases on their headache frequency 
and age at baseline, but at follow-up either did not have headache anymore or had 
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headache on < 7 days/month. Average time between baseline and follow-up 
examinations was 11.4 years (range 10-12.6 years). 
Ethics 
Signed informed consent was obtained from all participants in the HUNT2 and 
HUNT3 surveys, and the present study was approved by the Regional Committee for 
Medical Research Ethics (2012/2316/REK midt). 
Genome-wide quantification of DNA methylation 
A detailed description of sample handling, quantification of DNA methylation, data 
normalization and quality control is given in Supplemental Methods. Briefly, we 
performed array quantification of DNA methylation on genomic DNA isolated from 
leukocytes, after bisulfite conversion, using the Illumina Infinium 
HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA). For Stage 1, 96 
samples from 24 cases and 24 controls were analyzed. For Stage 2, 64 samples from 
16 cases and 16 controls were analyzed. The methylation level at each CpG site for 
each sample was calculated as a β-value, scaling from 0 (not methylated) to 1 (fully 
methylated). After sample-wise quality control steps, 36 cases and 35 controls 
contributed to the final analysis. An overview of the study design and participants in 
the final analysis are given in Figure 1. After marker-wise quality control steps, out 
of 485,775 CpG markers initially interrogated 431,282 and 436,517 markers were 
available for analysis in Stage 1 and Stage 2, respectively.  
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Analytic approach 
Baseline characteristics 
Baseline characteristics were compared between cases and controls by Fisher's exact 
test (for binary variables) or independent samples t-test (for continuous variables). 
The examined variables included known or suggested risk factors for the development 
of chronic daily headache (4, 13); age (continuous); low educational level (upper 
secondary school or less as highest education); self-reported daily use of tranquilizers 
last year (yes, no); current daily smoking (yes, no); low physical activity (< 1 hour 
light exercise per week); body-mass index (continuous); Hospital Anxiety and 
Depression Scale (HADS) for each of anxiety and depression (continuous) (14), 
chronic musculoskeletal complaints (yes, no) (15); gastrointestinal complaints (yes, 
no) (16), self-reported diabetes mellitus (yes, no) and self-reported rheumatoid or 
osteoarthritis (yes, no). Of the participants included in the study, 3 had missing 
information on physical activity and 1 on chronic musculoskeletal complaints.  
Association analysis and replication 
The effect of headache chronification (case-control status) was modeled on changes in 
DNA methylation levels. For each individual, normalized methylation level estimate 
(β-value) at baseline was subtracted from methylation level estimate at follow-up for 
each CpG site. Resulting methylation level changes at each CpG site were then 
compared between cases and controls using linear regression model adjusted for age, 
using the lm package in R software (17). Data from each stage was analyzed 
separately and the 20 CpG sites showing strongest association with chronification in 
Stage 1 were taken forward for replication in Stage 2. A Bonferroni-corrected p-value 
threshold (0.05/20 = 0.0025) was used to consider statistically significant replication. 
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Meta-analysis 
Subsequently, a fixed-effects meta-analysis was performed on DNA methylation data 
from Stage 1 and Stage 2, weighted by the inverse variance, using the GWAMA 
software (18). In total 436,549 CpG markers were present in either stage after quality 
control and could be used in the analysis, resulting in a Bonferroni-corrected p-value 
threshold of 1.15 x 10-7 (0.05/436,549). 
Characterization of top-ranking CpG sites 
Functional profiling of the meta-analysis top-ranking CpG sites was carried out using 
g:Profiler web-based software (19), see Supplemental Methods for a full description. 
Briefly, g:Profiler performs a statistical gene set enrichment analysis to find 
functional gene groups or biological pathways that are significantly over-represented 
in user-provided input. The results presented are based on the 200 top-ranking CpG 
sites from the meta-analysis, and results were considered significant if the multiple 
testing corrected p-value for the enriched group or pathway was ≤ 0.05. 
Characterization of gene expression in various human tissues was retrieved from the 
GTEx database (20). Although DNA methylation is largely tissue-specific, inter-
individual variation in DNA methylation has been shown to correlate between blood 
and brain for a subset of CpG sites (21). Correlation of DNA methylation levels 
between blood and brain at the top CpG sites was analyzed using the Blood Brain 
DNA Methylation Comparison tool (http://epigenetics.essex.ac.uk/bloodbrain) that 
utilizes DNA methylation data of blood and four different brain regions from matched 
samples (21).  
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Analysis of medication overuse  
Overuse of acute headache medications is a known risk factor for headache 
chronification. To evaluate to what extent medication overuse influenced the 
identified associations, the association analysis and meta-analysis was repeated 
stratified by medication overuse. Cases with or without medication overuse at follow-
up were analyzed separately against all controls. Results were visualized as forest 
plots using the metafor R package (version 1.9-8) (22). Additionally, unsupervised 
clustering of the samples was performed using the hclust R package, based on their 
methylation levels at follow-up at each of the 200 top-ranking CpG sites from the 
initial meta-analysis.  
 
Results 
Demographic variables and potential risk factors for CDH did not differ between 
cases and controls at baseline (Table 1). However, four participants reported 
medication overuse at baseline, and all four later developed CDH. Likewise no 
difference between cases and controls was found for the listed variables when Stage 1 
and Stage 2 were analyzed separately (data not shown). Average time between 
baseline and follow-up examinations was 11.4 years (range 10-12.6 years). At the 
time of follow-up 17 of 36 cases (47%) and 0 of 35 controls reported overuse of acute 
headache medication. 
 
The 20 CpG sites that demonstrated the strongest association with headache 
chronification in Stage 1 are listed in Table 2. Using the Bonferroni-corrected 
statistical significance level of 0.0025, none of these CpG sites reached statistical 
significance for replication in Stage 2. When data from the two stages were combined 
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in a fixed-effects meta-analysis, no CpG sites reached the multiple-testing corrected 
study-wide significance threshold of 1.15 x 10-7. The most strongly associated CpG 
marker was cg01010870 (p-value = 6.17 x 10-6), located near the transcription start 
site of the gene SH2D5 (Table 3) that is highly expressed in various regions of the 
human brain (Supplemental Figure 1). The second most strongly associated CpG 
marker cg11086695 (p-value = 6.95 x 10-6) is intergenic, located 76 kb downstream 
from NPTX2 and 141 kb downstream from TMEM130. For 6 of the top 10 CpG 
markers (Table 3), methylation levels in blood showed high correlation with 
methylation levels in one or several regions of the human brain at p-value < 0.05 (21), 
exemplified for the most significantly associated CpG site (cg01010870) in Figure 2.  
 
Genomic regions corresponding to the 200 top-ranking CpG sites from the meta-
analysis were significantly enriched for genes belonging to specific biological 
functions (Table 4, Supplemental Table 1). Statistically strongest enrichment was 
observed for "calcium ion binding" (p-value = 1.21 x 10-5), followed by "biological 
adhesion" (p-value = 4.23 x 10-5), "intracellular estrogen receptor signaling" (p-value 
= 0.02), and "negative regulation of homotypic cell-cell adhesion" (p-value = 0.04). 
 
When stratifying the meta-analysis for overuse of acute headache medications among 
cases, the associations for the 10 top-ranking CpG sites from the initial meta-analysis 
had the same direction and were of comparable strength in each of the two groups 
(Figure 3). Likewise, unbiased hierarchical cluster analysis based on the 200 top-
ranking CpG sites did not discriminate between cases with and without medication 
overuse (Figure 4). 
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Discussion 
This is, to our knowledge, the first study of epigenetic changes in headache 
chronification. Using a retrospective case-control design, DNA methylation changes 
were examined across the genome comparing patients who converted from episodic to 
chronic headache during a 11 year follow-up period with matched controls. In the 
discovery stage several CpG sites showed suggestive association to headache 
chronification, but these failed to replicate in the second stage. Combining association 
results from both stages in a fixed-effects meta-analysis we identified CpG sites that 
may point to genes involved in headache chronification. An enrichment was found for 
genes related to calcium ion binding, biological adhesion, and intracellular estrogen 
receptor signaling. 
 
Since cases in this study reported episodic headache at baseline and CDH at the time 
of follow-up, it is likely that they represent transformed rather than de-novo chronic 
headache. A limitation is however that the questionnaire-based assessment did not 
allow distinction of chronic migraine from other types of chronic headache. Previous 
epidemiological studies suggest that approximately half of those with CDH fulfill 
criteria for chronic migraine (1), making it likely that migraineurs contribute 
substantially to our case group.  
 
Medication overuse is a major risk factor for headache chronification, and it has 
previously been shown that medication overuse headache accounts for about half of 
the participants who report CDH in the HUNT population (13). A similar proportion 
was seen in this study with 17 of 36 cases (47%), but none of the controls, reporting 
medication overuse at the time of follow-up. Notably, all 4 participants who reported 
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medication overuse at baseline had developed chronic headache at follow-up. Given 
our design, it is feasible that at least some of the DNA methylation changes result 
from medication use. Still, when stratifying the meta-analysis results by cases with 
and without medication overuse, the strength and direction of association for the top 
10 loci from the meta-analysis were similar between the groups (Figure 3). Also, 
unsupervised hierarchical clustering of the samples based on methylation levels for 
the top 200 CpG sites did not discriminate cases with from cases without medication 
overuse (Figure 4). The results therefore suggest that medication overuse is unlikely 
to explain the identified associations. 
 
The most significant CpG site is at the SH2D5 gene, which encodes the SH2 Domain 
Containing 5 protein. The second strongest associated CpG site is 76 kb downstream 
from the nearest gene NPTX2, which encodes the Neuronal Pentraxin II protein. Both 
proteins are highly expressed in adult human brain (23, 24) (Supplemental Figure 1), 
and DNA methylation levels at the associated CpG sites are highly correlated between 
brain and blood (Table 3 and Figure 2). Both proteins have presumed roles in 
regulating synaptic plasticity. The SH2 Domain Containing 5 protein regulates 
synaptic plasticity through the control of Rac-GTP levels (25). Neuronal Pentraxin II 
regulates synaptic plasticity by acting as an inhibitor of excitatory synapses, through 
binding and clustering of glutamatergic AMPA receptors. Neuronal Pentraxin II is 
induced by neuronal activity, and has an assumed function in rebalancing excitation-
inhibition after periods of increased synaptic activity (23). Of interest, another of the 
top associated CpG markers is related to glutamate signaling. GRID2 encodes the 
glutamate receptor δ2, an ionotropic glutamate receptor which is expressed in several 
brain regions, with highest expression in the cerebellum (20, 26). Epigenetic 
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alteration of synaptic plasticity has been previously hypothesized as a possible 
mechanism of migraine chronification (6). Support for this comes from the 
experimental finding that synchronous neuronal activity, which also occurs in cortical 
spreading depression of the migraine aura (27), results in DNA methylation changes 
in brain-specific genes related to neuronal plasticity (28). One may envisage that as 
neuronal activity can cause epigenetic changes altering synaptic plasticity, migraine 
attacks in a feed-forward loop may promote subsequent migraine attacks leading to 
chronification. Our findings seem to provide at least some support for a role of 
synaptic plasticity in headache chronification. Regardless, it is far from clear whether 
such changes are a cause or consequence of frequent headache attacks. Furthermore, 
our findings may implicate that glutamatergic activity is implicated not only in 
migraine pathogenesis (29), but also in the transition from episodic to chronic 
headache. 
 
When considering the more extensive list of 200 top-ranking CpG sites, there is a 
statistically significant enrichment in genes related to several specific functional 
groups and pathways. The strongest enrichment was seen for calcium ion binding. 
Calcium ion binding and signaling is important in a wide range of cellular systems, 
including the synaptic release of neurotransmitters (30). While this presents a 
plausible mechanism for calcium ion imbalance in migraine pathogenesis, no genetic 
association to this or other calcium channels have been found for the common forms 
of migraine (31). The second strongest enrichment was found for genes involved in 
biological cell adhesion. Cell adhesion molecules have multiple roles in tissue 
development and function. In the human brain they play a major  role at synapses, 
where they control synaptic morphology and plasticity, and at the neurovascular unit 
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they form the molecular interface between the vascular and the central nervous 
system and are involved in the complex signaling between these systems (32, 33). 
Lastly, in this study of female subjects, we found enrichment for genes involved in 
estrogen receptor signaling. This corresponds well with lines of evidence suggesting a 
role of estrogen in migraine pathogenesis (34). Estrogen receptor signaling has also 
been discussed specifically in relation to possible epigenetic mechanisms in migraine, 
since the estrogen receptors predominantly assert their action through the epigenetic 
programming of target genes (6).  
 
Strengths of this study include the genome-wide assessment of DNA methylation 
sites, which allowed us to search for genetic loci associated with headache 
chronification without relying on previous hypotheses. Also, the headache 
classification used in this study has been validated by clinical interview. Given the 
longitudinal design we could determine DNA methylation levels in both cases and 
controls at two time points, before and after the development of chronic headache, 
which gave the possibility to detect changes in DNA methylation levels occurring 
during the natural course of the disease.  
 
Our study has clear limitations. Despite a large baseline population of 51,000 
individuals with available DNA who were characterized with respect to headache, and 
a follow-up time of 11 years, only 36 cases fulfilled inclusion criteria and could be 
used in the final analysis. This resulted in limited statistical power, as indicated by the 
failure to replicate signals identified in the discovery stage in the smaller replication 
sample. We therefore focused our subsequent analyses on the combined dataset of 
both stages in order to maximize the power to detect true signals. The loci identified 
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from the combined analysis aggregate in functionally meaningful pathways, 
indicating the presence of true signals. Nevertheless, the reported associations will 
require replication in independent samples, but given our complex design this will be 
challenging. This clearly demonstrates the difficulty of designing studies of epigenetic 
changes during the natural course of incident disease, and suggests that international 
collaboration is required to achieve robust sample sizes when using such a study 
design. Another limitation was that we determined DNA methylation in leucocytes 
from whole blood, whereas DNA methylation patterns are to a considerable extent 
tissue-specific, so our findings may not be representative of changes occurring in the 
more relevant tissue in headache, in particular the brain (8). However, for the majority 
of the top associated markers, DNA methylation levels in blood correlated well with 
DNA methylation levels in one or more brain regions, suggesting that our design has 
good potential to detect DNA methylation relevant to migraine. This is also in line 
with previous studies that have found that DNA methylation patterns in non-affected 
tissues such as blood can be of value, even leading to treatment decisions (35).  
 
A better understanding of the mechanisms underlying headache chronification will be 
important for developing better strategies to treat and prevent headaches in these 
severely affected patients. Epigenetic changes represent modifiable factors, and 
thereby offer potential targets for novel drug therapies (5). Although candidate 
regions identified in this study require independent replication and further 
characterization, this is a first step towards understanding epigenetic changes 
occurring in headache chronification. 
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Article highlights 
• The two CpG sites with strongest association to headache chronification were 
found in relation to genes that regulate synaptic plasticity. 
• Associated CpG sites also showed enrichment for genes involved in calcium 
ion binding, cell adhesion and estrogen receptor pathways. 
• The results suggest possible mechanisms by which epigenetic DNA 
methylation may be involved in the chronification of headache. 
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Figure legends 
Figure 1: Diagram of the study design and participants. A total of 36 female headache 
patients who transformed from episodic to chronic headache (‘cases’) between 
examinations at baseline and follow-up were matched against 35 female headache 
patients who did not transform to chronic headache (‘controls’). 
 
Figure 2: Correlation of DNA methylation in blood and four brain regions for 
cg01010870 (SH2D5). Top: Boxplot of the distribution of DNA methylation values 
for cg01010870 split by tissue. Bottom: Four scatterplots demonstrating the 
relationship between DNA methylation in whole blood and four brain regions: 
PFC=pre-frontal cortex; EC=entorhinal cortex; STG=superior temporal gyrus; 
CER=cerebellum. Plots are retrieved using the Blood Brain DNA Methylation 
Comparison tool (21). 
 
Figure 3. Forest plots showing meta-analysis results separately for cases with and 
without medication overuse. Meta-analysis beta-value (Beta) and its 95% confidence 
intervals (95% CI) for the top 10 CpG sites (cg01010870 to cg14118171) from the 
meta-analysis. 
 
Figure 4: Unsupervised clustering of cases based on the top 200 CpG sites from the 
meta-analysis. Unsupervised hierarchical clustering using methylation status at 
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follow-up did not discriminate between cases with (marked in yellow) and without 
medication overuse in either Stage 1 (A) or Stage 2 (B). 
 
Supplemental Figure 1. Relative expression of SH2D5 in various human tissues. 
Retrieved from the GTEx database (20). RPKM=Reads Per Kilobase of transcript per 
Million mapped reads. Box plots are shown as median and 25th and 75th percentiles; 
points are displayed as outliers if they are above or below 1.5 times the interquartile 
range. 
 
References 
[1] Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. 
Global prevalence of chronic migraine: a systematic review. Cephalalgia. 
2010;30:599-609. 
[2] Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia. 
2004;24:161-72. 
[3] Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, 
disability and economic burden associated with chronic daily headache, focusing on 
chronic migraine with or without medication overuse: a systematic review. 
Cephalalgia. 2011;31:837-50. 
[4] Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. 
Chronic migraine--classification, characteristics and treatment. Nature reviews 
Neurology. 2011;8:162-71. 
[5] Yan H, Tian S, Slager SL, Sun Z, Ordog T. Genome-Wide Epigenetic Studies 
in Human Disease: A Primer on -Omic Technologies. Am J Epidemiol. 2016;183:96-
109. 
 
 
20 
[6] Eising E, N AD, van den Maagdenberg AM, Ferrari MD. Epigenetic 
mechanisms in migraine: a promising avenue? BMC medicine. 2013;11:26. 
[7] Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and 
implications. Nat Rev Genet. 2011;13:97-109. 
[8] Labruijere S, Stolk L, Verbiest M, de Vries R, Garrelds IM, Eilers PH, et al. 
Methylation of migraine-related genes in different tissues of the rat. PloS one. 
2014;9:e87616. 
[9] Hagen K, Zwart JA, Aamodt AH, Nilsen KB, Brathen G, Helde G, et al. The 
validity of questionnaire-based diagnoses: the third Nord-Trondelag Health Study 
2006-2008. J Headache Pain. 2010;11:67-73. 
[10] Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovim G. Head-HUNT: validity 
and reliability of a headache questionnaire in a large population-based study in 
Norway. Cephalalgia. 2000;20:244-51. 
[11] Linde M, Stovner LJ, Zwart JA, Hagen K. Time trends in the prevalence of 
headache disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3). 
Cephalalgia. 2011;31:585-96. 
[12] Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J. Analgesic 
overuse among subjects with headache, neck, and low-back pain. Neurology. 
2004;62:1540-4. 
[13] Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for 
medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag 
Health Studies. Pain. 2012;153:56-61. 
[14] Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital 
Anxiety and Depression Scale. An updated literature review. Journal of 
psychosomatic research. 2002;52:69-77. 
 
 
21 
[15] Kvalheim S, Sandven I, Hagen K, Zwart JA. Smoking as a risk factor for 
chronic musculoskeletal complaints is influenced by age. The HUNT study. Pain. 
2013;154:1073-9. 
[16] Aamodt AH, Stovner LJ, Hagen K, Zwart JA. Comorbidity of headache and 
gastrointestinal complaints. The Head-HUNT Study. Cephalalgia. 2008;28:144-51. 
[17] R Core Team (2013). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
http://www.R-project.org/. 
[18] Magi R, Morris AP. GWAMA: software for genome-wide association meta-
analysis. BMC bioinformatics. 2010;11:288. 
[19] Reimand J, Arak T, Vilo J. g:Profiler--a web server for functional 
interpretation of gene lists (2011 update). Nucleic Acids Res. 2011;39:W307-15. 
[20] The Broad Institute of MIT and Harvard. GTEx Portal, database version 6. 
Retrieved February 26, 2016, from http://www.gtexportal.org/ [WWW document].  
[21] Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic 
variation across blood, cortex, and cerebellum: implications for epigenetic studies of 
neurological and neuropsychiatric phenotypes. Epigenetics. 2015;10:1024-32. 
http://epigenetics.iop.kcl.ac.uk/bloodbrain/. 
[22] Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J 
Stat Softw. 2010;36:1-48. 
[23] Chang MC, Park JM, Pelkey KA, Grabenstatter HL, Xu D, Linden DJ, et al. 
Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing 
interneurons. Nat Neurosci. 2010;13:1090-7. 
 
 
22 
[24] Pelkey KA, Barksdale E, Craig MT, Yuan X, Sukumaran M, Vargish GA, et 
al. Pentraxins coordinate excitatory synapse maturation and circuit integration of 
parvalbumin interneurons. Neuron. 2015;85:1257-72. 
[25] Gray EJ, Petsalaki E, James DA, Bagshaw RD, Stacey MM, Rocks O, et al. 
Src homology 2 domain containing protein 5 (SH2D5) binds the breakpoint cluster 
region protein, BCR, and regulates levels of Rac1-GTP. J Biol Chem. 
2014;289:35397-408. 
[26] Coutelier M, Burglen L, Mundwiller E, Abada-Bendib M, Rodriguez D, 
Chantot-Bastaraud S, et al. GRID2 mutations span from congenital to mild adult-
onset cerebellar ataxia. Neurology. 2015;84:1751-9. 
[27] Lauritzen M. Pathophysiology of the migraine aura. The spreading depression 
theory. Brain. 1994;117 ( Pt 1):199-210. 
[28] Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA, et al. Neuronal 
activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci. 
2011;14:1345-51. 
[29] Vecchia D, Pietrobon D. Migraine: a disorder of brain excitatory-inhibitory 
balance? Trends Neurosci. 2012;35:507-20. 
[30] Clapham DE. Calcium signaling. Cell. 2007;131:1047-58. 
[31] Nyholt DR, LaForge KS, Kallela M, Alakurtti K, Anttila V, Farkkila M, et al. 
A high-density association screen of 155 ion transport genes for involvement with 
common migraine. Hum Mol Genet. 2008;17:3318-31. 
[32] McCarty JH. Cell adhesion and signaling networks in brain neurovascular 
units. Curr Opin Hematol. 2009;16:209-14. 
[33] Sakisaka T, Takai Y. Cell adhesion molecules in the CNS. J Cell Sci. 
2005;118:5407-10. 
 
 
23 
[34] Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of 
hormones and their impact on vascular diseases. J Headache Pain. 2012;13:177-89. 
[35] Schubeler D. Function and information content of DNA methylation. Nature. 
2015;517:321-6. 
 
 
 
1 
Epigenetic DNA methylation changes associated with 
headache chronification: A retrospective case-control study  
 
SUPPLEMENTAL METHODS 
 
Blood sampling and DNA isolation 
Blood samples were donated from subjects in the HUNT2 or HUNT3 studies at the 
time of inclusion. Serum was separated from whole blood within 2 hours by 
centrifugation, placed in a refrigerator together with a blood clot or EDTA whole 
blood, and transported in a cooler within 1 - 3 days to the HUNT Biobank, where it 
was stored at -70°C. DNA was isolated from leukocytes from thawed blood clots or 
EDTA whole blood by using Gentra Puregene Blood Kit (Qiagen Diagnostics GmbH, 
Hamburg, Germany) or MasterPure DNA purification Kit for blood, Buffy Coat DNA 
Purification Protocol (Epicentre) and stored at -20°C. DNA concentrations were 
quantified using PicoGreen reagents, and every eight normalized sample was 
spectrophotometrically tested a second time using NanoDrop (ND1000 or ND8000) 
(Thermo Fisher Scientific Inc., Waltham, MA, USA). Purity was assessed based on 
the A260/A280 ratios. 
Genome-wide quantification of DNA methylation 
Bisulfite conversion and array quantification of DNA methylation was performed in 
two separate stages. In Stage 1, 96 samples from 24 cases and 24 controls were 
analyzed at the Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland; 
in Stage 2, 64 samples from 16 cases and 16 controls were analyzed at the Wellcome 
Trust Sanger Institute, Cambridge, UK. Bisulfite conversion of 1 µg of the DNA 
sample was performed using the EZ-96 DNA Methylation Kit (Zymo Research, 
Irvine, CA, USA) according to the manufacturer's protocol. 5 µl of the bisulfite 
converted DNA were used for genome-wide methylation profiling using the Illumina 
Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) 
according to manufacturer's protocol. After hybridization and washing, the BeadChips 
were scanned using the Illumina HiScan SQ scanner. The efficiency of the bisulfite 
conversion was checked according to the manufacturer's protocol. 
Data normalization and quality control  
Raw image data were imported into the GenomeStudio (Illumina version 2011.1) 
Methylation module (version 1.9), which was used to extract the fluorescent signal 
intensities and pre-normalize the data. Briefly, background signal intensity was 
subtracted from the raw signal intensity values and data were normalized with respect 
to the Illumina internal control probes. The methylation level was calculated as a β-
value (AVG_Beta), scaling from 0 (not methylated) to 1 (fully methylated, 
representing the fraction of methylated DNA molecules at the corresponding CpG site 
in the assayed sample. These data were exported from the GenomeStudio as standard 
Illumina report files and further normalized and analyzed with custom scripts. Data 
for stages 1 and 2 were jointly quantile-normalized (1) with R software (version 3.2.3) 
(2) as described by Grundberg et al. (3), followed by the PCA analysis of β-values to 
detect any potential outliers and other quality control steps. 
In sample-wise quality control steps, altogether 9 samples were excluded. Of 
the 40 cases and 40 controls selected for methylation typing (24 cases and 24 controls 
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in Stage 1; 16 cases and 16 controls in Stage 2), samples were excluded because of 
low DNA concentration (n = 2); because they were red staining outliers (n = 2); had 
gender mismatch between methylation typing and phenotype annotation (n = 1); or 
were sample outliers as identified by PCA analysis (n = 4). Samples were also 
excluded if after above-mentioned exclusions they did not have data for both time 
points available, resulting in 36 cases (23 in Stage 1 and 13 in Stage 2) and 35 
controls (21 in Stage 1 and 14 in Stage 2) contributing to the final analysis.  
Marker (CpG site) wise quality control was carried out similarly to Grundberg 
and colleagues (3). Briefly, out of 485,775 CpG markers initially interrogated by the 
HumanMethylation450 chip, all markers were excluded that had a call rate ≤ 0.9; 
overlapped with single nucleotide variants with minor allele frequency ≥ 5% in the 
CEU panel of the 1000Genomes Project (4); or overlapped with copy number variants 
in 1000Genomes Project. After quality control 431,282 and 436,517 markers were 
available for analysis in Stage 1 and Stage 2, respectively.  
Genomic annotation of interrogated CpG sites 
To assign each assayed CpG marker to their corresponding gene, genomic and gene-
level annotations provided by Illumina (HumanMethylation450_15017482_v.1.1.csv, 
based on the human reference sequence assembly version GRCh37/hg19) were used. 
In order to get the latest genomic annotation of the meta-analysis top-ranking CpG 
sites for functional profiling, chromosomal coordinates of the top 1000 CpG sites 
were converted to the current version of the human reference sequence assembly 
(GRCh38/hg38) with the liftOver web-based batch conversion tool 
(http://genome.ucsc.edu/cgi-bin/hgLiftOver, by using default parameters). 
Blood cell composition estimates 
White blood cell (WBC) composition is regarded a main source of variation in DNA 
methylation analyses of whole blood. To check for possible WBC composition biases 
in our samples, the WBC composition was estimated from the DNA methylation 
profiles using the R-package minfi (version 1.8.9) developed by Houseman et al. (5). 
No significant differences were found in white blood cell composition between cases 
and controls in either Stage 1 or Stage 2.  
Functional profiling of top-ranking CpG sites using g:profiler 
Functional profiling of the meta-analysis top-ranking CpG sites was carried out by 
utilizing g:Profiler web-based software (version r1536, http://biit.cs.ut.ee/gprofiler) 
using Ensembl 83 genomic annotations, Gene Ontology release 2016-01-21 and 
KEGG biological pathways release 2016-01-25 (6). Considering all genes in user-
provided gene lists or chromosomal regions, g:Profiler performs statistical gene set 
enrichment analysis to find which functional gene groups or biological pathways are 
significantly over-represented in user-provided input. As our input CpG site 
coordinates were ordered by their meta-analysis association p-values, the ‘Ordered 
query’ option was used, and we also required at least 3 CpG site-related genes in any 
tested functional group or pathway (option ‘Size of query / term intersection’). Only 
CpG markers that were successfully called and showed the same effect direction in 
both stages were included, in order to enrich the input for true positive signals. The 
optimal size of the input set of CpG sites for the gene set enrichment analysis depends 
on a balance between including a sufficient number of sites to enable the detection of 
enrichment, while limiting the input set so that the highest possible proportion of true 
signals is obtained. To this end, the analysis was run using incrementally larger input 
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sets, including 10, 20, 50, 100 and 200 meta-analysis top-ranking CpG markers 
resepectively. The sets including 10, 20, 50 and 100 markers did not return significant 
enriched functional groups or pathways and are therefore not presented. The results 
were considered significant if the multiple testing corrected p-value for enriched 
group or pathway was ≤ 0.05.  
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